Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

512 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The effect of tumor downsizing on surgical complexity during nephrectomy after immune checkpoint inhibitors for metastatic renal cell carcinoma.
Pignot G, Margue G, Bigot P, Lang H, Balssa L, Roubaud G, Borchiellini D, Bensalah K, Schlürmann F, Ladoire S, Parier B, Bernhard JC, Cassuto O, Albigès L, Thibault C, Ingels A, Cherifi F, Waeckel T, Flippot R, Geoffrois L, Walz J, Gravis G, Barthélémy P. Pignot G, et al. Among authors: walz j. World J Urol. 2025 Jan 2;43(1):54. doi: 10.1007/s00345-024-05361-y. World J Urol. 2025. PMID: 39747746
Nephrectomy After Complete Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma: A New Surgical Challenge?
Pignot G, Thiery-Vuillemin A, Walz J, Lang H, Bigot P, Werle P, Balssa L, Geoffrois L, Leblanc L, Albigès L, di Nunno V, Bensalah K, Ladoire S, Gravis G, Barthélémy P. Pignot G, et al. Among authors: walz j. Eur Urol. 2020 Jun;77(6):761-763. doi: 10.1016/j.eururo.2019.12.018. Epub 2020 Jan 3. Eur Urol. 2020. PMID: 31911011 No abstract available.
Oncological Outcomes of Delayed Nephrectomy After Optimal Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma.
Pignot G, Thiery-Vuillemin A, Albigès L, Walz J, Lang H, Balssa L, Parier B, Geoffrois L, Bensalah K, Schlürmann F, Ladoire S, Bigot P, Borchiellini D, Cassuto O, Thibault C, Ingels A, Saldana V, Roubaud G, Bernhard JC, Gravis G, Barthélémy P. Pignot G, et al. Among authors: walz j. Eur Urol Oncol. 2022 Oct;5(5):577-584. doi: 10.1016/j.euo.2022.07.002. Epub 2022 Jul 17. Eur Urol Oncol. 2022. PMID: 35853818
Efficacy of hyperthermic intravesical chemotherapy (HIVEC) in patients with non-muscle invasive bladder cancer after BCG failure.
Pignot G, Baboudjian M, Lebacle C, Chamouni A, Lechevallier E, Irani J, Tillou X, Waeckel T, Monges A, Doisy L, Walz J, Gravis G, Mourey E, Duperron C, Masson-Lecomte A. Pignot G, et al. Among authors: walz j. World J Urol. 2023 Nov;41(11):3195-3203. doi: 10.1007/s00345-023-04332-z. Epub 2023 Feb 22. World J Urol. 2023. PMID: 36811732
Efficacy and tolerance of hyperthermic intravesical chemotherapy (HIVEC) according to the number of instillations administered.
Gabriel PE, Pignot G, Baboudjian M, Lebacle C, Chamouni A, Lechevallier E, Irani J, Tillou X, Waeckel T, Monges A, Walz J, Gravis G, Duperron C, Carpentier X, Klein C, Masson-Lecomte A. Gabriel PE, et al. Among authors: walz j. World J Urol. 2024 Sep 11;42(1):516. doi: 10.1007/s00345-024-05219-3. World J Urol. 2024. PMID: 39259376
512 results